Xenon Pharmaceuticals, Inc. has entered into a collaboration with Genentech, a member of the Roche Group, for the discovery and validation of new therapeutic targets and mechanisms for treating pain. Xenon will employ its Extreme Genetics discovery platform to explore rare phenotypes associated with an inability to perceive pain or spontaneous severe pain. This new agreement expands upon the companies strategic alliance established in 2012 for the discovery and development of compounds and compa...